Acino Holding AG (FRA:S3H) 5-Year Yield-on-Cost % : 0.59 (As of May. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Acino Holding AG 5-Year Yield-on-Cost %?

Acino Holding AG's yield on cost for the quarter that ended in Dec. 2013 was 0.59.

The historical rank and industry rank for Acino Holding AG's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:S3H' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.59 Med: 1.48 Max: 2.89
Current: 0.59

During the past 11 years, Acino Holding AG's highest Yield on Cost was 2.89. The lowest was 0.59. And the median was 1.48.

FRA:S3H's 5-Year Yield-on-Cost % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.13 vs FRA:S3H: 0.59

Competitive Comparison of Acino Holding AG's 5-Year Yield-on-Cost %

For the Drug Manufacturers - General subindustry, Acino Holding AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acino Holding AG's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's 5-Year Yield-on-Cost % falls into.

Acino Holding AG 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Acino Holding AG is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Acino Holding AG (FRA:S3H) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Acino Holding AG 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acino Holding AG (FRA:S3H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » 5-Year Yield-on-Cost %

Traded in Other Exchanges

N/A

Address

Website

http://www.acino-pharma.com

Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines